P62-ZZ chemical inhibitor
AssigneeID4Pharma, LLC
InventorsXiang-Qun Xie, Garson David Roodman, Kyaw-Zeyar Myint, Noriyoshi Kurihara
Life of this patent
Estimating the term…
Abstract
A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.
Claims17
A method for treating multiple myeloma in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound of structural Formula I:
- or a pharmaceutically acceptable salt or ester thereof, wherein:
- Ar is an arylene or heteroarylene;
- R1 has a structure of:
- wherein W is an alkanediyl;
- X is —NR5—, wherein R5 is H;
- and Y is a hydroxyalkyl, an aminoalkyl, or a carboxylalkyl;
- each R2 is the same or different and has a structure of:
- wherein Z is —NR6— or —O—;
- R6 is H;
- Z1 is (—CH2—);
- Cy is a 6-membered aryl ring;
- and
- each R4 is the same or different halogen;
- c is 1;
- a is 2;
- and
- b is O.
A method of inhibiting multiple myeloma cell growth, comprising contacting multiple myeloma cells with a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of:
- or a pharmaceutically acceptable salt or ester thereof, wherein:
- Ar is an arylene or heteroarylene;
- R1 has a structure of:
- wherein W is an alkanediyl;
- X is —NR5—, wherein R5 is H;
- and
- Y is a hydroxyalkyl, an aminoalkyl, or a carboxylalkyl;
- each R2 is the same or different and has a structure of:
- wherein Z is —NR6— or —O—;
- R6 is H;
- Z1 is (—CH2—);
- Cy is a 6-membered aryl ring;
- and
- each R4 is the same or different halogen;
- c is 1;
- a is 2;
- and b is 0.
Dependencies are inferred from the claim text.